DE69508938D1 - Transdermales arzneistoff-abgabesystem - Google Patents

Transdermales arzneistoff-abgabesystem

Info

Publication number
DE69508938D1
DE69508938D1 DE69508938T DE69508938T DE69508938D1 DE 69508938 D1 DE69508938 D1 DE 69508938D1 DE 69508938 T DE69508938 T DE 69508938T DE 69508938 T DE69508938 T DE 69508938T DE 69508938 D1 DE69508938 D1 DE 69508938D1
Authority
DE
Germany
Prior art keywords
therapeutic agent
pct
cyclodextrin
date jan
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69508938T
Other languages
English (en)
Other versions
DE69508938T2 (de
Inventor
Arto Olavi Urtti
Maria Riitta Sutinen
Timo Petteri Paronen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Arto Olavi Urtti
Maria Riitta Sutinen
Timo Petteri Paronen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arto Olavi Urtti, Maria Riitta Sutinen, Timo Petteri Paronen filed Critical Arto Olavi Urtti
Publication of DE69508938D1 publication Critical patent/DE69508938D1/de
Application granted granted Critical
Publication of DE69508938T2 publication Critical patent/DE69508938T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
DE69508938T 1994-07-08 1995-06-20 Transdermales arzneistoff-abgabesystem Expired - Lifetime DE69508938T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9413866A GB2290964A (en) 1994-07-08 1994-07-08 Transdermal drug delivery system
PCT/FI1995/000358 WO1996001626A1 (en) 1994-07-08 1995-06-20 Transdermal drug delivery system

Publications (2)

Publication Number Publication Date
DE69508938D1 true DE69508938D1 (de) 1999-05-12
DE69508938T2 DE69508938T2 (de) 1999-09-16

Family

ID=10758074

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69508938T Expired - Lifetime DE69508938T2 (de) 1994-07-08 1995-06-20 Transdermales arzneistoff-abgabesystem

Country Status (12)

Country Link
US (1) US5817332A (de)
EP (1) EP0764020B1 (de)
JP (1) JP3734267B2 (de)
AT (1) ATE178485T1 (de)
AU (1) AU2740595A (de)
CA (1) CA2193129C (de)
DE (1) DE69508938T2 (de)
DK (1) DK0764020T3 (de)
ES (1) ES2130622T3 (de)
GB (1) GB2290964A (de)
GR (1) GR3030369T3 (de)
WO (1) WO1996001626A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980033113A (ko) * 1996-10-25 1998-07-25 야스다케 히지 국소 마취제 수용액, 국소 마취제의 용해도를 개선시키는 방법, 신경독성이 감소된 국소 마취제 및 국소 마취제의 신경 독성을 감소시키는 방법
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
DE19810951B4 (de) * 1998-03-13 2005-09-29 Ciba Speciality Chemicals Holding Inc. Verwendung eines textilen Materials als transdermales Abgabesystem sowie Verfahren zu seiner Herstellung
DE19814087A1 (de) * 1998-03-30 1999-10-14 Lohmann Therapie Syst Lts Feuchtigkeitsaktivierbares therapeutisches System
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
JP2004500360A (ja) * 1999-12-16 2004-01-08 ダーマトレンズ, インコーポレイテッド 皮膚浸透促進剤としての水酸化物放出剤
US6719997B2 (en) 2000-06-30 2004-04-13 Dermatrends, Inc. Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers
US6586000B2 (en) * 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6673363B2 (en) 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6689378B1 (en) 1999-12-28 2004-02-10 Kimberly-Clark Worldwide, Inc. Cyclodextrins covalently bound to polysaccharides
US7179483B2 (en) 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US6878693B2 (en) 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
BR0307935A (pt) * 2002-02-25 2005-03-29 Diffusion Pharmaceuticals Llc Sais de trans carotenóide bipolares e seus usos
ES2293193T5 (es) 2004-07-13 2012-06-13 Bayer Schering Pharma Oy Sistema de suministro retardado con descarga inicial controlada
ES2780200T3 (es) * 2005-02-24 2020-08-24 Diffusion Pharmaceuticals Llc Carotenoides trans, formulación y usos
WO2006135785A2 (en) * 2005-06-10 2006-12-21 Medical College Of Georgia Research Institute Compositions and methods for treating immune disorders
US9446017B2 (en) 2005-08-11 2016-09-20 Augusta University Research Institute, Inc. Compositions and methods for treating herpes simplex virus
AU2007235002A1 (en) * 2006-04-07 2007-10-18 Allergan, Inc. Compositions including relatively water insoluble/unwettable drugs and methods for using same
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
EP2589588A1 (de) 2007-04-13 2013-05-08 Diffusion Pharmaceuticals Llc Verwendung von bipolaren Trans-Carotinoiden als Vorbehandlung und bei der Behandlung von peripherer Gefässkrankheit
CA2703946A1 (en) * 2007-10-31 2009-05-07 Diffusion Pharmaceuticals Llc A new class of therapeutics that enhance small molecule diffusion
US10130689B2 (en) 2009-06-22 2018-11-20 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
US20130017188A1 (en) 2009-07-31 2013-01-17 The Brigham And Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
CA2794565C (en) 2010-04-08 2018-08-21 Emory University Substituted androst-4-ene diones
CN105287473A (zh) 2010-06-02 2016-02-03 扩散药品有限公司 包含双极性反式类胡萝卜素的组合物及其应用
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
EP2704726B1 (de) 2011-05-04 2018-10-31 Trustees of Boston University Protonenantriebskraftstimulation zur potenzierung von aminoglycosid-antibiotika gegen persistente bakterien
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
EP2543370A1 (de) 2011-07-06 2013-01-09 Georgia Health Sciences University Research Institute, Inc. Zusammensetzungen und Verfahren zur Behandlung des Herpes-simplex-Virus
WO2013071049A1 (en) 2011-11-10 2013-05-16 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
EP3036226B1 (de) 2013-08-22 2020-01-08 The General Hospital Corporation Hemmer der humanen 12/15-lipoxygenase
US11382883B2 (en) 2013-08-29 2022-07-12 Trustees Of Boston University Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
ES2856748T3 (es) 2013-10-07 2021-09-28 Teikoku Pharma Usa Inc Dispositivos de administración transdérmica de dexmedetomidina y métodos para el uso de los mismos
US10987342B2 (en) 2013-10-07 2021-04-27 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
CA2924233C (en) 2013-10-07 2018-10-23 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
TWI629061B (zh) * 2013-10-07 2018-07-11 美商帝國製藥美國股份有限公司 包含右美托嘧啶(dexmedetomidine)經皮組成物之疼痛處理用方法及組成物
CA2934453A1 (en) * 2013-12-18 2015-06-25 Gnt, Llc Compositions and methods for treatment of glaucoma
TW201609200A (zh) 2013-12-18 2016-03-16 丸石製藥股份有限公司 含水型貼劑
WO2016196664A1 (en) 2015-06-01 2016-12-08 Cedars-Sinai Medical Center Methods and use of compounds that bind to rela of nf-kb
BR112018001441A2 (pt) 2015-07-28 2018-09-11 Vyome Biosciences Pvt Ltd antibacterianos terapêuticos e profiláticos
US10493049B2 (en) 2016-02-10 2019-12-03 Niracle LLC Applicator-based transdermal drug delivery system for administration of drugs in combination with topical formulations
WO2017165667A1 (en) 2016-03-24 2017-09-28 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
CN110337290A (zh) 2016-12-31 2019-10-15 比奥克斯塞尔医疗股份有限公司 舌下右旋美托咪啶用于治疗激越的用途
BR112020026672A2 (pt) 2018-06-27 2021-03-30 Bioxcel Therapeutics, Inc. Formulações de filme contendo dexmedetomidina e métodos para produzi-las
TWI772807B (zh) 2019-05-27 2022-08-01 日商救急藥品工業股份有限公司 外用製劑
JP2022540706A (ja) 2019-07-19 2022-09-16 バイオエクセル セラピューティクス,インコーポレイテッド 鎮静作用のないデクスメデトミジン治療レジメン
EP4308088A1 (de) 2021-11-08 2024-01-24 Weiyong Li Transdermales arzneimittelabgabesystem zur abgabe eines arzneimittels an einen patienten

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756710A (en) * 1985-04-05 1988-07-12 Merck & Co., Inc. pH-Mediated drug delivery system
US4749574A (en) * 1986-04-14 1988-06-07 Fujisawa Pharmaceutical Co., Ltd. Sustained-release transdermal delivery preparations
US4781924A (en) * 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
HU210921B (en) * 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
AU661726B2 (en) * 1991-10-16 1995-08-03 Timo Petteri Paronen Peroral drug delivery system
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation

Also Published As

Publication number Publication date
CA2193129C (en) 2007-11-06
JP3734267B2 (ja) 2006-01-11
EP0764020B1 (de) 1999-04-07
CA2193129A1 (en) 1996-01-25
US5817332A (en) 1998-10-06
WO1996001626A1 (en) 1996-01-25
JPH10502388A (ja) 1998-03-03
AU2740595A (en) 1996-02-09
DK0764020T3 (da) 1999-10-18
ES2130622T3 (es) 1999-07-01
GR3030369T3 (en) 1999-09-30
GB2290964A (en) 1996-01-17
GB9413866D0 (en) 1994-08-24
DE69508938T2 (de) 1999-09-16
EP0764020A1 (de) 1997-03-26
ATE178485T1 (de) 1999-04-15

Similar Documents

Publication Publication Date Title
ATE178485T1 (de) Transdermales arzneistoff-abgabesystem
RS52577B (en) ONE-DAY OXYCODON FORMULATIONS
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
ATE298259T1 (de) Vorrichtung zur lokalen verabreichung einer arznei in einer körperhöhle
ATE237330T1 (de) Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
ATE198152T1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
BR0010869A (pt) Método para administrar um corticosteróide a um segmento posterior de um olho e dispositivo de liberação sustentada implantável
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
TR200001998T1 (tr) Kontrollü salıverilen tolterodin uygulamak için ilaç formülasyonu
NZ520083A (en) The modification of a patient's blood with ultra-violet light for the treatment of congestive heart failure
SE8703034L (sv) Oralt terapeutiskt system med systemisk verkan
KR950702409A (ko) 방출 조절 모르핀 제제(controlled release morphine preparation)
DE69634009D1 (de) Implantierbare vorrichtung zur kontrollierten abgabe von arzneimitteln unmittelbar an einen inneren teil des körpers
MEP28208A (en) Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
ATE202923T1 (de) Orale dosierungsform und verfahren zur behandlung von schmerzzuständen in dermundhöhle
DE69431800T2 (de) Arzneiverabreichungssystem
ID28160A (id) Sistem pengobatan untuk pemberian fenilasetilglutamina, fenilasetilisoglutamina dan/atau fenilasetat.
DK0856312T3 (da) Anvendelse af trospiumchlorid til fremstilling af et lægemiddel til behandling af blæresygdomme
HK1038310A1 (en) Compositions and methods for treating intracellular infections.
ATE135203T1 (de) System zur peroralen arzneimittelabgabe
UA37510A (uk) Спосіб лікування загрози передчасного переривання вагітності
MY124346A (en) Medicated chewing gum delivery system for nicotine
MX9601033A (es) Nanosuspensiones para administracion intravenosa.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ORION CORP., ESPOO, FI

8381 Inventor (new situation)

Free format text: URTTI, ARTO OLAVI, KUOPIO, FI SUTINEN, MARIA RIITTA, SIILINJAERVI, FI PARONEN, TIMO PETTERI, KUOPIO,FI

Free format text: URTTI, ARTO OLAVI, KUOPIO, FI SUTINEN, MARIA RIITTA, SIILINJAERVI, FI PARONEN, TIMO PETTERI, KUOPIO, FI